This is not a chemotherapy-specific response and TIE2-expressing PvTAMs also accumulate at the tumor vasculature post treatment of vasculature disruptive agents such as combretastatin A4 phosphate [41] and anti-VEGF therapies [42] as well as post irradiation [43] which limits the efficacy of these therapies. This evidence concerns the gene VEGFA and neoplasm.